颈动脉支架置入双联抗血小板治疗中的氯吡格雷抵抗与替格瑞洛替换
前瞻性收集2016年11月至2020年12月连续接受颈动脉支架置入并采用乙酰水杨酸联合氯吡格雷双联抗血小板治疗的患者数据,用阻抗聚集仪评估抗血小板药物效果。200例患者中38例(19%)出现氯吡格雷抵抗,替换为替格瑞洛(90 mg,每日两次)后聚集仪测试有效率为100%。血小板计数与氯吡格雷抵抗相关(P=0.001)。
要点
- 颈动脉支架置入患者中氯吡格雷抵抗发生率为19%(38/200)。
- 氯吡格雷抵抗患者替换为替格瑞洛(90 mg,每日两次)后聚集仪测试有效率为100%。
- 血小板计数与氯吡格雷抵抗相关(P=0.001)。
核心结论
- 在颈动脉支架置入患者中,氯吡格雷对19%的患者无效。
- 血小板计数似乎影响这一现象。
- 在这些患者中,氯吡格雷被替格瑞洛有效替换。
研究设计与样本
- 前瞻性收集2016年11月至2020年12月连续接受颈动脉支架置入治疗显著狭窄并使用乙酰水杨酸联合氯吡格雷双联抗血小板治疗的患者数据。
- 排除已在使用其他噻吩吡啶类药物的患者。
- 采用阻抗聚集仪测试评估抗血小板药物效果。
- 主要终点为评估氯吡格雷抵抗发生率及替格瑞洛作为替代疗法的有效性。
- P值<0.05认为有统计学意义。
主要发现
- 200例患者(女性80例,40%)因颈动脉狭窄接受支架置入(94%无症状)。
- 38例患者(19%)观察到氯吡格雷抵抗现象,其中氯吡格雷被替换为替格瑞洛(90 mg,每日两次),聚集仪测试有效率为100%。
- 血小板计数与氯吡格雷抵抗相关(P=0.001)。
- 30天内无支架血栓形成,也无大出血事件。
- 共发生12/200例主要不良心血管事件(6%),其中替格瑞洛组1例,氯吡格雷组11例(2.6% vs 6.7%,P=0.55)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS: Resistance to the pharmacological effect of clopidogrel in patients undergoing dual antiplatelet therapy for carotid stenting may increase the risk of periprocedural neurological events. The purpose of the study was to describe the phenomenon of clopidogrel resistance in a series of patients undergoing carotid stenting. METHODS: Data of patients who consecutively underwent carotid stenting from November 2016 to December 2020 for a significant stenosis and who underwent a dual antiplatelet therapy using acetyl-salicylic acid and clopidogrel were prospectively collected. Patients who were already taking a different thienopyridine were excluded. The effectiveness of antiplatelet drugs was assessed by the impedance aggregometry test. Primary endpoint was to evaluate the incidence of clopidogrel resistance and the effectiveness of ticagrelor as alternative therapy. P values < 0.05 were considered statistically significant. RESULTS: Two-hundred patients (80 females, 40%) underwent stenting for carotid stenosis (94% asymptomatic). The phenomenon of clopidogrel resistance was observed in 38 patients (19%), in whom clopidogrel was replaced by ticagrelor (90 mg/bis in die) with 100% effectiveness at aggregometry test. Platelet counts was associated to clopidogrel resistance (P = 0.001). There was no stent thrombosis at 30 days, neither major hemorrhagic events; a total of 12/200 major adverse cardiovascular events occurred (6%), including 1 in the group of patients who took ticagrelor and 11 in group of patients under clopidogrel (2.6% versus 6.7%, P = 0.55). CONCLUSIONS: Clopidogrel was ineffective in 19% of patients undergoing carotid stenting. Platelet count seemed to affect this phenomenon. In these patients, clopidogrel was effectively replaced by ticagrelor.
引用
- Mazzaccaro D, Giannetta M, Ranucci M, et al. Clopidogrel Resistance and Ticagrelor Replacement in Dual Antiplatelet Therapy for Carotid Artery Stenting. Ann Vasc Surg. 2022. PMID: 36270550. doi:10.1016/j.avsg.2022.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。